A clinical-stage leader in immune-stimulatory vaccines for cancer announced the publication of its favorable long-term Overall Survival (OS) data from a Phase I trial evaluating a universal cancer vaccine candidate, UV1, in combination with checkpoint inhibitor ipilimumab, in patients with metastatic malignant melanoma.

UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

Published in the Frontiers in Immunology journal on May 11, 2021, Norway-based Ultimovacs ASA’s UV1 vaccine candidate achieved the primary endpoints of safety and tolerability.